These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11316542)

  • 1. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
    Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients.
    Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
    Am J Clin Oncol; 2004 Aug; 27(4):350-60. PubMed ID: 15289727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
    Jeremic B; Shibamoto Y; Acimovic L; Djuric L
    J Clin Oncol; 1995 Feb; 13(2):452-8. PubMed ID: 7844608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1157-63. PubMed ID: 21640518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer.
    Shibamoto Y; Jeremic B; Acimovic L; Milicic B; Nikolic N
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):295-300. PubMed ID: 11380214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer.
    Jeremic B; Shibamoto Y; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):343-8. PubMed ID: 10760429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
    Jeremić B; Milicić B; Acimović L; Milisavljević S
    J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
    Jeremic B; Milicic B; Acimovic L; Milisavljevic S
    J Clin Oncol; 2005 Feb; 23(6):1144-51. PubMed ID: 15718310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients.
    Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
    Am J Clin Oncol; 2004 Dec; 27(6):616-25. PubMed ID: 15577441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non-small cell lung cancer.
    Jeremic B; Jevremovic S; Mijatovic L; Milisavljevic S
    Cancer; 1993 Jun; 71(11):3732-6. PubMed ID: 8387885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy.
    Jeremic B; Shibamoto Y
    Lung Cancer; 1995 Aug; 13(1):21-30. PubMed ID: 8528637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
    Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
    Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.
    Jeremic B; Shibamoto Y
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):303-8. PubMed ID: 8567330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
    Jeremić B; Miličić B; Milisavljevic S
    Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
    Jeremić B; Milićić B
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):426-32. PubMed ID: 17306936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.
    Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
    J Clin Oncol; 1997 Mar; 15(3):893-900. PubMed ID: 9060525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.